Letter to the Editor: Gut microbiota–bile acid crosstalk - Prevotellaceae NK3B31 and 7-ketolithocholic acid drive metabolic benefits of distal bowel resection with preservation of terminal ileum

This letter-to-the-editor comments on a multiomics study investigating why a surgical procedure called distal bowel resection with terminal ileum preservation (DBRPI) improves blood sugar control. The original research found that after this surgery, a specific gut bacterium from the Prevotellaceae NK3B31 group becomes more abundant, and this bacterium drives up levels of a bile acid called 7-ketolithocholic acid (7-KLCA). That bile acid then activates a receptor inside liver cells called FXR (farnesoid X receptor), which in turn dials down the liver's production of new glucose — a process called gluconeogenesis that is overactive in metabolic disease. The letter highlights the novelty of pinpointing a single microbial taxon and a specific bile acid as the key mediators, rather than describing broad microbiome shifts. It also flags the real-world therapeutic angle: if this axis drives the benefit, then probiotics containing this bacterium or drugs mimicking 7-KLCA might reproduce the surgery's metabolic effects without the operation. The authors raise important unanswered questions, including whether the bacterium is truly causal (not just correlated), how 7-KLCA levels change in blood over time, and whether the gut hormone GLP-1 interacts with FXR signalling in this context. Overall, the work positions gut microbiota–bile acid crosstalk as a targetable pathway for treating metabolic liver disease and type 2 diabetes.

• DBRPI surgery was associated with enrichment of the Prevotellaceae NK3B31 group, a specific bacterial taxon identified through multiomics profiling as a central mediator of postoperative metabolic improvement.
• Elevated Prevotellaceae NK3B31 abundance was mechanistically linked to increased intestinal and systemic levels of 7-ketolithocholic acid (7-KLCA), a secondary bile acid with FXR-agonist properties.
• FXR activation by 7-KLCA suppressed hepatic gluconeogenic gene expression in functional assays, providing a molecular explanation for improved glucose homeostasis following DBRPI.
• The letter identifies three major open questions unresolved by the original study: causal validation of the microbial taxon (e.g., via germ-free colonisation models), pharmacokinetics of serum 7-KLCA post-surgery, and potential GLP-1/FXR crosstalk in mediating glucose regulation.

This is an invited letter-to-the-editor commenting on a primary research article by Xu et al. published in the World Journal of Gastroenterology; the letter itself does not generate new data. The underlying study employed a multiomics approach (likely combining 16S rRNA or metagenomic sequencing with targeted metabolomics for bile acid profiling) alongside functional cell or animal assays to interrogate the Prevotellaceae NK3B31/7-KLCA/FXR axis in the context of DBRPI surgery. Specific sample sizes, animal models, and follow-up durations for the primary study are not reported in this letter's abstract. Methods details here are best-effort inferences from described outcomes and standard multiomics workflows; confidence is moderate.

Because this article is a commentary, it introduces no new experimental evidence and cannot confirm causality between Prevotellaceae NK3B31 enrichment and metabolic benefit — a limitation the letter itself acknowledges. The original study's sample size, patient demographics, and surgical cohort characteristics are not disclosed in this abstract, making it impossible to assess generalisability. Key mechanistic gaps flagged by the authors include the absence of serum 7-KLCA pharmacokinetic data across postoperative time points and unresolved interaction between GLP-1 signalling and FXR activation. The next critical experiment would be a germ-free mouse colonisation study using Prevotellaceae NK3B31 to establish causality, followed by a dose-finding study of 7-KLCA analogs in a diet-induced obesity model.

This letter extends [§72], which maps procedure-specific microbiota remodelling after bariatric surgery, by providing a molecularly resolved example of how a defined post-surgical microbial shift (Prevotellaceae NK3B31 enrichment) translates into a discrete metabolic benefit via a bile acid second messenger. It parallels [§73], where the Mediterranean diet mobilises the bile acid/gut microbiome axis to reduce colorectal cancer risk, highlighting that the same FXR-centred signalling logic operates across dietary and surgical interventions in distinct clinical contexts. The work also extends [§100], which argues for moving beyond reductionist microbiome science toward ecological and causal frameworks, by demonstrating precisely the kind of taxon-specific, mechanism-first analysis that framework calls for — while simultaneously exposing the causal validation gap that remains. Additionally, it resonates with [§24], a single-strain dropout screen that mechanistically links individual microbial species to metabolic phenotypes, underscoring the emerging consensus that targeted, strain-level resolution is essential for translating microbiome findings into therapeutics.

• Microbiota remodeling after bariatric surgery: Procedure-specific dynamics and metabolic implications
  Directly parallel surgical context — examines how bariatric procedures reshape the microbiome and drive metabolic outcomes, enabling a procedure-by-procedure comparison of which microbial taxa and metabolites mediate glucose improvement.
• Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
  Same bile acid/FXR mechanistic axis but in a dietary (Mediterranean diet) rather than surgical setting, allowing readers to assess whether 7-KLCA or related bile acids are a convergent effector molecule across interventions.
• A single-strain dropout screen reveals mechanistic links between microbial ecology and metabolism
  Uses a single-strain dropout screen to causally link individual microbial species to metabolic phenotypes — the exact experimental design needed to validate the causal role of Prevotellaceae NK3B31 flagged as an open question in this letter.
• The human microbiome at translational crossroads: an ecological and causal perspective
  Provides the theoretical framework for ecological and causal microbiome inference that this letter implicitly calls for when it raises the question of causal validation, making it essential context for understanding the study's methodological frontier.
• The Effect of OptiFibre Dietary Fiber on Carbohydrate Metabolism and Intestinal Microbiota Metabolism in Patients With Type 2 Diabetes Mellitus
  Examines dietary fibre effects on carbohydrate metabolism and intestinal microbiota in a metabolic disease population, offering a non-surgical comparator for microbiota-mediated glucose regulation that could inform whether the DBRPI-associated taxa are diet-responsive.